Daisuke Morioka, Toru Kubota, Hitoshi Sekido, Kenichi Matsuo, Shuji Saito, Yasushi Ichikawa, Itaru Endo, Shinji Togo, Hiroshi Shimada – 30 December 2003 – The aim of this study was to determine whether the minimum necessary volume of a moderate fatty liver graft was similar to the normal liver volume and to elucidate means for improving the function of the transplanted fatty liver if it were inferior in volume to a normal liver under conditions of permissible cold preservation. Nine‐week‐old male Wistar rats were used.

Urmila Khettry, Namrata Anand, Peter N. Faul, W. David Lewis, Elizabeth A. Pomfret, James Pomposelli, Roger L. Jenkins, Fredric D. Gordon – 30 December 2003 – Although recurrent primary biliary cirrhosis (PBC) after liver transplantation (LT) has been reported, the full spectrum of changes and progression to fibrosis and cirrhosis is not yet established. We performed a detailed retrospective clinicopathologic analysis of 43 patients who underwent LT for PBC.

Raymund R. Razonable, Carlos V. Paya – 30 December 2003 – Cytomegalovirus (CMV) infection remains a highly prevalent systemic complication following orthotopic liver transplantation (LT), accounting for a significant increase in morbidity and affiliated costs. However, unlike other immunosuppressed groups of population, CMV infection of the central nervous system in LT is rarely diagnosed, either clinically or postmortem. Furthermore, in 20% of the LT patients who develop preterminal neurological complications, the etiology remains undetermined.

Lydia M. Petrovic – 30 December 2003 – Background: Chronic rejection (CR) in liver allografts show a rapid onset and progressive course, leading to graft failure within the first year after transplantation. Most cases are preceded by episodes of acute cellular rejection (AR), but histological features predictive for the transition toward CR are not well documented. Method: We assessed the predictive value of centrilobular necrosis, central vein endothelialitis (CVE), central vein fibrosis, and lobular inflammation in the development of CR.

Hugo E. Vargas, Tomasz Laskus, Marek Radkowski, Jeff Wilkinson, Vijay Balan, David D. Douglas, M. Edwyn Harrison, David C. Mulligan, Kevin Olden, Debra Adair, Jorge Rakela – 30 December 2003 – Patients with chronic hepatitis C frequently report tiredness, easy fatigability, and depression. The aim of this study is to determine whether hepatitis C virus (HCV) replication could be found in brain tissue in patients with hepatitis C and depression. We report two patients with recurrent hepatitis C after liver transplantation who also developed severe depression.

Robert J. Fontana, Anna S.F. Lok – 30 December 2003 – Background & Aims: Lamivudine has become a main therapeutic option for treating hepatitis B virus (HBV) infection. Although drug resistance develops, the clinical course after selection of antiviral‐resistant HBV mutants seems to be benign. However, we observed a severe clinical course of hepatitis B infection in several liver transplant recipients after the emergence of lamivudine resistance. This was associated with high viral load in the blood.

John R. Lake – 30 December 2003

Ed Gane – 30 December 2003 – 1Treatment of established recurrent hepatitis C with interferon‐α monotherapy does not achieve sustained virologic response (SVR).2Treatment of established recurrent hepatitis C with combination interferon plus ribavirin achieves SVR rates of 17% to 27%, but dropout rates approach 30%.3Pretransplant prophylaxis against recurrent hepatitis C with combination interferon plus ribavirin is poorly tolerated in patients with decompensated hepatitis C cirrhosis.4Posttransplant prophylaxis with combination interferon plus ribavirin prevents both recurrent viremia and he

Didier Samuel – 30 December 2003

Salvatore Gruttadauria, Carlo Scotti Foglieni, Angelo Luca, Augusto Lauro, Cataldo Doria, Ignazio R. Marino – 30 December 2003